#India #Mumbai #pharmaceuticals #Piramal Pharma #FY26 Results

Piramal Pharma Limited Reports Mixed Results for FY26

Piramal Pharma Limited, a prominent player in the global pharmaceutical and health sector, has recently released its financial results for the fourth quarter (Q4) and the entire fiscal year 2026, ending March 31. The report paints a complex picture of the company’s performance, highlighting both challenges and areas of growth.

Financial Overview

In the consolidated financial highlights, Piramal Pharma reported an operational revenue of ₹2,752 crores for Q4FY26, slightly declining from ₹2,754 crores in the same quarter last year. This indicates a marginal year-on-year change of 0%. For the entire fiscal year, the total revenue stood at ₹8,869 crores, marking a drop of 3% when compared to ₹9,151 crores in FY25.

The company’s main sectors, particularly the Contract Development and Manufacturing Organization (CDMO), saw a decline in revenue, contributing ₹1,708 crores, down 4% from the previous year. However, the Complex Hospital Generics (CHG) segment showed impressive growth with a 7% increase year-on-year, generating ₹755 crores. Meanwhile, the Consumer Healthcare (PCH) arm witnessed a robust 17% growth, reaching ₹320 crores this quarter.

Amidst these figures, the company reported an EBITDA of ₹507 crores, reflecting a significant 16% decline compared to the last year’s ₹603 crores. EBITDA margins also faced pressure, decreasing to 18% from 22% in Q4FY25, attributing this to operational challenges including inventory management and market dynamics.

Operational Highlights

Nandini Piramal, the Chairperson, characterized FY26 as a transitional phase for the company, heavily influenced by external and internal challenges. Despite noted difficulties, such as inventory destocking and softer market traction in inhalation anesthesia outside the U.S., the company finished the fiscal year with momentum across its various divisions. Notably, the biopharma funding landscape began to recover from late 2025, which the management deems promising for future contract development opportunities.

Investments during the year totaled approximately US$94 million, focusing on both growth and maintenance projects, showcasing a strategic commitment to expanding their production capacities, particularly in sterile injectables.

Strategic Insights and Future Outlook

Piramal’s diversified ventures have positioned it well for future growth. Positive signs emerged from the recent acquisition of Kenalog®, which aims to broaden the CHG portfolio with minimal additional costs. Additionally, the company's market share in inhalation anesthesia has improved to 47%, showcasing its leadership in this niche market.

The momentum in the Consumer Healthcare sector, driven by key brands such as Little's and Lacto Calamine, demonstrates substantial growth, particularly in e-commerce, which experienced a 48% revenue increase year-on-year, accounting for 27% of total sales in this segment.

Looking ahead, Piramal Pharma anticipates that all three core business segments—CDMO, CHG, and PCH—are well-placed to deliver enhanced growth in FY27. This optimism is fueled by expected increases in order inflows and operational efficiencies aimed at boosting EBITDA and net profits.

In summary, while Piramal Pharma faced some hurdles during FY26, the company’s robust strategic outlook underlines a path forward that capitalizes on its diversified portfolio and operational advancements.

Earnings Conference Call

Piramal Pharma will host a conference call on April 29, 2026, at 9:30 AM IST to discuss the financial results and future directions with investors and analysts. This conference will provide an opportunity for stakeholders to engage directly with company leadership regarding their strategic initiatives and operational outlook.

For those interested in staying updated on Piramal Pharma's progress, further details can be found on their website.

Conclusion

In conclusion, Piramal Pharma Limited’s results for FY26 are a tapestry of challenges and potential. With a clear focus on innovation and market adaptability, the company appears poised for an influential upcoming fiscal year.